LCI699

Phase 2Small molecule

Novartis

LCI699 is one of 39 small molecule programs targeting Essential Hypertension. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Essential HypertensionActive, not recruiting

HypertensionActive, not recruiting

HyperaldosteronismActive, not recruiting

Essential HypertensionPhase 2

Active, not recruiting

HypertensionPhase 2

Active, not recruiting

HyperaldosteronismPhase 2

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Edarbi

Takeda

Preclinical

10 2

Benicar

Novartis

Preclinical

7 3

Apresoline

Novartis

Preclinical

7 4

Edarbi

Takeda

Preclinical

4 5

LCI699

Novartis

Phase 2

2 6

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 7

Winrevair

Alphagan

Avastin

1 10

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Cushing's Syndrome

NCT03708900

Clinical

Trials by Indication[1]

Hypertension2 trials

A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT00817414·63 enrolled

A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT00817635·155 enrolled

Cushing's Syndrome1 trial

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

Recruiting·RRECORDATI GROUP·Phase 2·NCT03708900·12 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of LCI699 in Cushing's Disease Patients

Completed· Novartis logo

Novartis·Phase 2·NCT01331239·31 enrolled

Hyperaldosteronism1 trial

Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism

Completed· Novartis logo

Novartis·Phase 2·NCT00732771·12 enrolled

Essential Hypertension1 trial

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT00758524·628 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for LCI699. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LCI699 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LCI699. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

LCI699

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hypertension2 trials

Cushing's Syndrome1 trial

Safety and Efficacy1 trial

Hyperaldosteronism1 trial

Essential Hypertension1 trial

References

Drug Info

Quick Facts

Related News